Compare Eli Lilly And Co (LLY) vs Occidental Petroleum Corporation (OXY) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Occidental Petroleum (OXY) trades at $55.36, up 0.91% with a bullish technical signal. The company shows strong profitability with 22.42% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights capital spending reductions and Permian Basin growth potential. Analyst consensus is positive with a $65.38 price target representing 18% upside potential from current levels.

OXY presents a compelling investment case with improving debt metrics and consistent earnings outperformance. However, declining revenue trends from $36.6B in 2022 to $21.6B in 2025 and oil price sensitivity remain key risks. The stock's premium valuation (P/E 74.14) requires sustained execution to justify current levels amid volatile energy markets.